API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Apixaban is an oral, reversible, and selective active site inhibitor of FXa. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.
Lead Product(s): Apixaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Apixaban-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
It alleged that Micro Labs has already listed the apixaban product in 2.5 mg and 3 mg tablet strengths under the probable brand name Apivas on various third party websites and has also applied for registration of the trade mark Apivas before the Indian Trade Mark Registry.
Lead Product(s): Apixaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Eliquis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2021
Details:
HEAL-COVID will enrol patients when they are discharged from hospital, following their first admission for COVID-19. They will be randomised and given one of two drugs – apixaban and atorvastatin – and their progress tracked.
Lead Product(s): Apixaban
Therapeutic Area: Infections and Infectious Diseases Product Name: Elquis
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2021
Details:
The Phase 3 clinical trials will analyse the use of Bristol Myers Squibb/Pfizer’s anticoagulant, Eliquis (apixaban 2.5mg) in patients discharged from the hospital following a diagnosis of moderate-to-severe Covid-19.
Lead Product(s): Apixaban
Therapeutic Area: Infections and Infectious Diseases Product Name: Eliquis
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
Details:
Apixaban is an anticoagulant, or blood thinner. It is used for patients with health problems caused by a blood clot.
Lead Product(s): Apixaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020